Clinical trials: Macular Degeneration, Dry
Dry Age-Related Macular Degeneration, Geographic Atrophy
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Background: Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots.
- Trial name
- NCT04339764
- Testing
- iPSC-derived RPE/PLGA transplantation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Eye Institute (NEI)
Dry Age-related Macular Degeneration
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.
- Trial name
- NCT04065490
- Testing
- Valeda Light Delivery System
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- LumiThera, Inc.
Dry Age-related Macular Degeneration
QA102 Phase II Study in Subjects With Dry AMD
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA)…
- Trial name
- AMEND (NCT05536752)
- Testing
- QA102
- Where
- 29 sites in United States
- Volunteers
- 150 people
- Sponsor
- Smilebiotek Zhuhai Limited
Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD)
MIND-AMD Study: a Multidisciplinary Investigation of Neuroretinal Damage in Age-related Macular Degeneration.
Age-related macular degeneration (AMD) is the major cause of legal blindness in developed countries. Intermediate AMD represents the most frequent stage.
- Conditions
- Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD), AMD Population - Intermediate or Advanced AMD, AMD and Macular Edema
- Trial name
- MIND-AMD (NCT07847151)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Dry Age-related Macular Degeneration, Geographic Atrophy
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea.
- Trial name
- PATCH-AMD (NCT06557460)
- Testing
- Surgical implantation of the CPCB-RPE1 implant
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regenerative Patch Technologies, LLC
Dry Age-related Macular Degeneration
A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)
The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM) as provided by the Valeda Light Delivery System in participants with…
- Trial name
- NCT06351605
- Testing
- Valeda® Light Delivery System
- Where
- 6 sites in United States, Norway
- Volunteers
- 500 people
- Sponsor
- LumiThera, Inc.
Epiretinal Membrane, Dry Age Related Macular Degeneration
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
- Conditions
- Epiretinal Membrane, Dry Age Related Macular Degeneration, Macular Abnormalities, Retina Disease
- Trial name
- NCT07680244
- Testing
- PathFinder 1.0 on CIRRUS HD-OCT
- Where
- 6 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Carl Zeiss Meditec-Dublin CoCe
Dry Age-related Macular Degeneration
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm
- Trial name
- NCT07770828
- Testing
- OCU410
- Where
- 3 sites in United States
- Volunteers
- 237 people
- Sponsor
- Ocugen
Dry Age-related Macular Degeneration
PRIMA US-Feasibility Study in Atrophic Dry AMD
In this early feasibility trial the safety and performance of the new retinal prothesis PRIMA is tested in five subjects suffering from atrophic dry age related macular degeneration.
- Trial name
- PRIMA-FS-US (NCT03392324)
- Testing
- PRIMA
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Science Corporation
Dry Age Related Macular Degeneration
A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration
The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD).
- Trial name
- NCT07024732
- Testing
- PST-611
- Where
- 2 sites in France
- Volunteers
- 8 people
- Sponsor
- Eyevensys
Dry Age-Related Macular Degeneration, AMD
Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration
The goal of this clinical trial is to evaluate the efficacy and safety of an electric stimulator for medical use by personal (LRTPM1) in patients with early to intermediate dry age-related macular degeneration.
- Trial name
- NCT07700147
- Testing
- Transcutaneous Electrical Stimulation
- Where
- 3 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Nu Eyne Co., Ltd.
Age Related Macular Degeneration (AMD), Age Related Macular Degeneration
Evaluating the Relationship Between Function and Structure Using Data From a GA Natural History Cohort
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration that leads to progressive and irreversible vision loss.
- Conditions
- Age Related Macular Degeneration (AMD), Age Related Macular Degeneration, AMD, Geographic Atrophy
- Trial name
- ARCHERY (NCT07424235)
- Volunteers
- 60 people
- Sponsor
- IRCCS Ospedale San Raffaele
Age-Related (Dry) Macular Degeneration
Ocular Proteomics Testing In Chronic Atrophy
Study to evaluate the safety of routine diagnostic anterior chamber paracentesis (ACP) for proteomic profiling in patients with geographic atrophy (GA)
- Trial name
- OPTICA (NCT07298291)
- Testing
- AC Tap (anterior chamber paracenthesis)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- ClinOmicsAI
Dry Age-related Macular Degeneration
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration
In this study, the principle functionality of the device will be tested in humans for the first time. The study will evaluate the extent to which patients with atrophic dry age related macular degeneration (AMD) have evoked light…
- Trial name
- PRIMA FS (NCT03333954)
- Testing
- PRIMA Bionic Vision System
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Science Corporation
Age-Related (Dry) Macular Degeneration
Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection
The goal of this observational clinical study is to learn if DeepMSI AI detects age-related macular degeneration (AMD) biomarkers with sensitivity and specificity equivalent to experienced clinicians in adults over 40 years old.
- Trial name
- NCT07446582
- Testing
- Retina imaging device (MSI-120) and AI (DeepMSI AI)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- AI-Spectral
Geographic Atrophy, Dry Age Related Macular Degeneration
Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration
This study investigates the effects of subtenon autologous platelet-rich plasma (PRP) injections on retinal structure and visual function in patients with advanced dry age-related macular degeneration (AMD).
- Trial name
- GA-PRP (NCT07428798)
- Testing
- Subtenon Autologous Platelet-Rich Plasma Injection
- Where
- Turkey (Türkiye)
- Volunteers
- 14 people
- Sponsor
- Marmara University Pendik Training and Research Hospital
Dry Age-related Macular Degeneration, Macular Degeneration
FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD
This was an open label first in human Phase I/II multicentre study of GT005 in subjects with Macular Atrophy due to Age-related macular degeneration (AMD).
- Conditions
- Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Eye Diseases
- Trial name
- NCT03846193
- Testing
- GT005, GT005 / Device: Orbit™ Subretinal Delivery System
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 56 people
- Sponsor
- Gyroscope Therapeutics Limited
Dry Age-related Macular Degeneration
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration…
- Trial name
- NCT04566445
- Testing
- GT005
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 255 people
- Sponsor
- Gyroscope Therapeutics Limited
Dry Age-related Macular Degeneration
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
The purpose of this clinical study was to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration…
- Trial name
- EXPLORE (NCT04437368)
- Testing
- GT005
- Where
- 55 sites in United States, Australia and 6 more
- Volunteers
- 98 people
- Sponsor
- Gyroscope Therapeutics Limited
Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD
This is a Phase 1/2 study, multi-center, dose-escalation interventional study of BS01 in subjects with GA secondary to dry AMD. Part 1 is an open label dose-escalation study; Part 2 is a dose-expansion study with dose(s) selected…
- Trial name
- NCT07158775
- Testing
- BS01
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Bionic Sight LLC